Nothing Special   »   [go: up one dir, main page]

Cesar-Silva et al., 2022 - Google Patents

The endolysosomal system: the acid test for SARS-coV-2

Cesar-Silva et al., 2022

View HTML
Document ID
14886401616604123213
Author
Cesar-Silva D
Pereira-Dutra F
Moraes Giannini A
Jacques G. de Almeida C
Publication year
Publication venue
International Journal of Molecular Sciences

External Links

Snippet

This review aims to describe and discuss the different functions of the endolysosomal system, from homeostasis to its vital role during viral infections. We will initially describe endolysosomal system's main functions, presenting recent data on how its compartments …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Similar Documents

Publication Publication Date Title
Wong et al. The SARS-coronavirus infection cycle: a survey of viral membrane proteins, their functional interactions and pathogenesis
Salata et al. Ebola virus entry: from molecular characterization to drug discovery
Blaess et al. COVID-19/SARS-CoV-2 infection: lysosomes and lysosomotropism implicate new treatment strategies and personal risks
Cesar-Silva et al. The endolysosomal system: the acid test for SARS-coV-2
Nieto-Torres et al. Relevance of viroporin ion channel activity on viral replication and pathogenesis
Daussy et al. “Repair Me if You Can”: membrane damage, response, and control from the viral perspective
Moreira et al. How influenza virus uses host cell pathways during uncoating
Melano et al. Effects of basic amino acids and their derivatives on SARS-CoV-2 and influenza-A virus infection
Shroff et al. The molecular interplay between human coronaviruses and autophagy
Al Adem et al. Inhibition of SARS-CoV-2 entry into host cells using small molecules
Zhang et al. Recent progress on exosomes in RNA virus infection
Ginex et al. Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods
Checkmahomed et al. In vitro combinations of baloxavir acid and other inhibitors against seasonal influenza A viruses
Chu et al. Autophagy in HCV replication and protein trafficking
Vande Burgt et al. Requirements within the Ebola viral glycoprotein for tetherin antagonism
Barile et al. Potential therapeutic targeting of coronavirus spike glycoprotein priming
Ye et al. An oleanolic acid derivative inhibits hemagglutinin-mediated entry of influenza A virus
Gerlach et al. The membrane-active phytopeptide cycloviolacin O2 simultaneously targets HIV-1-infected cells and infectious viral particles to potentiate the efficacy of antiretroviral drugs
Mironov et al. COVID-19 biogenesis and intracellular transport
Zeyen et al. Hepatitis B virus exploits ERGIC-53 in conjunction with COPII to exit cells
Gale et al. Host proteins identified in extracellular viral particles as targets for broad-spectrum antiviral inhibitors
Peralta-Garcia et al. Entrectinib—A SARS-CoV-2 inhibitor in human lung tissue (HLT) cells
Kongsomros et al. Anti-SARS-CoV-2 activity of extracellular vesicle inhibitors: screening, validation, and combination with remdesivir
Kianpour et al. Nanoparticles for coronavirus control
D’Avila et al. Lipid metabolism modulation during SARS-CoV-2 infection: A spotlight on extracellular vesicles and therapeutic prospects